Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Active not recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Breast 1

Conditions

Breast Neoplasms 163Endometrial Neoplasms 13Ovarian Neoplasms 12Fallopian Tube Neoplasms 5Recurrence 4Neoplasms 4Neoplasm Metastasis 4Carcinoma, Intraductal, Noninfiltrating 4Triple Negative Breast Neoplasms 3Breast Diseases 3Breast Cancer Metastatic 3Prostatic Neoplasms 2Leiomyosarcoma 2Carcinoma, Lobular 2Advanced Breast Cancer 2Uterine Neoplasms 1Uterine Cervical Neoplasms 1Squamous Cell Carcinoma of Head and Neck 1Solid Tumor 1Small Cell Lung Carcinoma 1Polycystic Ovary Syndrome 1Pathologic Complete Response 1Pancreatic Neoplasms 1Pain 1Osteoporosis 1Neoplastic Cells, Circulating 1Neoadjuvant Operable Breast Cancer 1Multiple Endocrine Neoplasia Type 1 1Medullary cystic kidney disease 1 1Lymphangioleiomyomatosis 1

Interventions

trastuzumab biosimilar HLX02 1exemestane 1X-Rays 1Trastuzumab 1Taxes 1TVB-2640 1Specimen Handling 1Paclitaxel 1PF-05280014 1Ontruzant 1Ogivri 1Magnetic Resonance Spectroscopy 1Letrozole 1Fulvestrant 1Disulfides 1CT-P6 1Biopsy 1Anastrozole 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2 × Advanced Breast Carcinoma × Letrozole × Clear all
NCT03179904 2026-05-05

TVB-2640 and Trastuzumab With Paclitaxel or Endocrine Therapy for Treatment of HER2 Positive Metastatic Breast Cancer

Mayo Clinic

Phase 2 Active not recruiting
17 enrolled 10 charts
Breast

Advanced Breast Carcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡